Fulcrum Therapeutics (NASDAQ:FULC) Announces Earnings Results, Misses Expectations By $0.07 EPS

Fulcrum Therapeutics (NASDAQ:FULC) released its quarterly earnings results on Thursday. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.07), Zacks reports.

Fulcrum Therapeutics Stock Down 1.6%

Shares of FULC opened at $3.68 on Friday. Fulcrum Therapeutics has a 1 year low of $2.83 and a 1 year high of $15.74. The business’s 50 day simple moving average is $3.74 and its 200-day simple moving average is $5.59.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, Fulcrum Therapeutics presently has an average rating of “Reduce” and an average target price of $8.20.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.